Home/Pipeline/CSL324

CSL324

Severe COVID-19

Phase 3Active (EUA granted)N/A

Key Facts

Indication

Severe COVID-19

Phase

Phase 3

Status

Active (EUA granted)

Company

CSL

About CSL

CSL Limited's mission is to deliver innovative biotherapies and vaccines to patients with serious and rare diseases, leveraging a diversified portfolio and integrated business model. The company has achieved global leadership in plasma-derived therapies and influenza vaccines, underscored by strategic acquisitions like Vifor Pharma and a $1.5 billion U.S. manufacturing expansion. Its strategy centers on deepening expertise in immunology, hematology, and nephrology, driving growth through R&D investment, operational excellence, and geographic expansion to meet rising global demand for its critical therapies.

View full company profile

Therapeutic Areas

Hematology Immunology Nephrology Respiratory Vaccines

Other Severe COVID-19 Drugs

Drug	Company	Phase	Status
SCN-101 (COVID-19 hIVIG)	Scinai Immunotherapeutics	Phase 2/3	Completed
Severe Covid	Genclis	Discovery	Active
Exvastat Program	Numedicus	Phase 2	Active